Soy Isoflavones & Equol

Soy isoflavones occur in soybeans primarily as glycosides (daidzin, genistin, glycitin), which the body cannot absorb intact — gut β-glucosidases must first hydrolyse the sugar moiety to release the aglycone forms (daidzein, genistein, glycitein) before absorption. As a result, aglycone-rich preparations (often produced by koji or microbial fermentation of soy) are absorbed faster than equivalent glycosides — published pharmacokinetic studies report time-to-peak (Tmax) for the aglycones around 5–7 hours versus around 9 hours for the glycosides. The two forms are not interchangeable for label-dose calculations: a milligram value for 'soy isoflavones' may refer to glycoside weight or to the aglycone-equivalent weight, and the distinction matters for both efficacy and Japan's safety-intake guidance.

Equol — specifically S-equol — is a downstream metabolite produced from the isoflavone daidzein by certain gut bacteria. Equol has higher binding affinity for estrogen receptor β than its precursor daidzein, longer plasma half-life, and is hypothesised to mediate many of the benefits attributed to soy isoflavones. The catch: not everyone has the gut microbiota to produce it. Published epidemiology consistently reports equol-producer prevalence around 50–55% in Asian (including Japanese) adults consuming regular soy diets, versus around 20–35% in Western adults. This means the same soy intake will deliver materially different in-vivo equol exposure across populations — the rationale for direct fermented S-equol supplementation as an alternative pathway.

Japan's Food Safety Commission (Cabinet Office) issued safety guidance in 2006 setting a recommended safe upper limit of 70–75 mg/day of isoflavone aglycone equivalents from total dietary intake, with an additional 30 mg/day cap on the increment contributed by supplements (i.e., the supplement contribution should not exceed 30 mg/day on top of habitual food intake). This is dietary guidance for the Japanese market, not a hard regulatory ceiling, but it is used as a design reference by Japanese formulators and is relevant to Tokuho and FFC submissions involving soy isoflavones. Brands designing for the Japanese market should set per-serving aglycone-equivalent dose with this guidance in mind.

EQUELLE® is a dietary supplement launched by Otsuka Pharmaceutical in Japan in April 2014. It is produced by fermenting soy germ with Lactococcus 20-92, a lactic-acid bacterium that Otsuka isolated in 2002 and that converts daidzein in soy to S-equol. This pathway allows consumers who lack natural equol-producing gut microbiota to obtain S-equol directly from a supplement. Otsuka subsequently launched EQUELLE in the US (2017) and introduced a jelly format (EQUELLE Gelée, 2018). EQUELLE® and the Lactococcus 20-92 platform are Otsuka-owned IP — competing fermented-S-equol products would need an independent IP and regulatory pathway.

Two pathways apply. (1) Tokuho (FOSHU / 特定保健用食品): individually pre-approved by the Consumer Affairs Agency, requiring company-specific clinical evidence and a long review timeline. Several legacy Tokuho approvals exist for soy isoflavone products with bone-support endpoints. (2) Foods with Function Claims (FFC / 機能性表示食品), introduced in 2015: a notification (not pre-approval) system. Manufacturers submit safety and efficacy evidence before sale; multiple soy isoflavone FFC notifications now exist for endpoints including bone maintenance. Brands choosing between the two should weigh evidence cost, time-to-market, and the strength of the claim language each system permits.